EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the Wegovy pill. Already approved in the US, the pill has seen huge uptake, with more than 1 million people using it within the first 4 months of its launch.
Developed by Novo Nordisk, it is intended for adults living with obesity, or those who are overweight and have at least one weight-related comorbidity, such as cardiovascular disease, hypertension, or type 2 diabetes.
The new oral formulation could broaden access for patients reluctant to use injections. Unlike some competing oral therapies, Wegovy pill also carries no drug-drug restrictions in its proposed label where one medicine can react with another producing harmful side effects.
“We are encouraged by CHMP’s positive opinion for Wegovy pill,” said Novo…
